Results 41 to 50 of about 470,990 (120)

Asymptomatische erythematöse Plaque am Unterschenkel

, 2023
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 21, Issue 7, Page 813-815, July 2023.
Inga Hansen, Finn Abeck, Isabel Heidrich, Stefan W. Schneider, Nina Booken   +4 more
wiley   +1 more source

Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations

Cancer Management and Research, 2022
Caitlin Crimp,1 Ameya Gangal,2 Erica S Tarabadkar,3 Michi M Shinohara1,4 1Division of Dermatology, University of Washington, Seattle, WA, USA; 2School of Medicine, Emory University, Atlanta, GA, USA; 3Department of Dermatology, Emory University School of
Crimp C, Gangal A, Tarabadkar ES, Shinohara MM   +3 more
doaj  

Current state of medical care for patients with mycosis fungoides and Sézary syndrome at a German university hospital – a cross‐sectional study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Studies on the state of medical care for patients with cutaneous T‐cell lymphoma (CTCL) are limited. To date, only secondary data analyses are available for Germany. Patients and Methods Cross‐sectional study conducted over a one‐year recruitment period (01 March 2024 to 28 February 2025) in the dermatological department of a German ...
Inga Hansen‐Abeck, Larissa Kölln, Finn Abeck, Glenn Geidel, Stefan W. Schneider, Nina Booken   +5 more
wiley   +1 more source

Ropeginterferon‐α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pegylated interferon‐α2a became the off‐label alternative for treating mycosis fungoides/Sézary syndrome (MF/SS) after non‐pegylated interferons were withdrawn. This study aimed to evaluate the safety and efficacy of ropeginterferon‐α2b in MF/SS. Patients and methods We performed a retrospective multicenter analysis at
Stefanie Porkert, Juliette M. Kersten, Rosanne Ottevanger, Hanna Schratter, Regina Fink‐Puches, Van Anh Nguyen, Farzaneh Sadeghyar, Johanna Latzka, Franz Trautinger, Magdalena Hoellwerth, Peter Koelblinger, Nicole Pfannschmidt, Nina Haering, Johannes Griss, Maarten H. Vermeer, Constanze Jonak   +15 more
wiley   +1 more source

Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 4, Page 495-502, April 2026.
Summary Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce.
Patrick Schummer, Caroline Glatzel, Philipp Schrüfer, Ingulf Lawrenz, Gabor Dobos, Ulrike Wehkamp, Svea Hüning, René Stranzenbach, Jan P. Nicolay, Matthias Goebeler, Marion Wobser   +10 more
wiley   +1 more source

Behandlung des CD30‐positiven kutanen T‐Zell‐Lymphoms mit Brentuximab vedotin und Strahlentherapie – retrospektive multizentrische Analyse

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 4, Page 495-503, April 2026.
Zusammenfassung Hintergrund und Zielsetzung Während Brentuximab vedotin (BV) oder Strahlentherapie (RTx) gängige Behandlungsoptionen für CD30‐positive kutane T‐Zell‐Lymphome (CTCL) sind, wurde über die Wirksamkeit und Verträglichkeit ihrer gleichzeitigen oder aufeinanderfolgenden Anwendung nur selten berichtet.
Patrick Schummer, Caroline Glatzel, Philipp Schrüfer, Ingulf Lawrenz, Gabor Dobos, Ulrike Wehkamp, Svea Hüning, René Stranzenbach, Jan P. Nicolay, Matthias Goebeler, Marion Wobser   +10 more
wiley   +1 more source

Pediatric Hypopigmented Mycosis Fungoides: A Narrative Literature Review of Phototherapy Dosing Regimens

Dermatology Research and Practice, Volume 2026, Issue 1, 2026.
Background Mycosis fungoides is the most common type of childhood‐onset primary cutaneous T‐cell lymphoma, and hypopigmented mycosis fungoides (hMF) is a rare, diversely presenting form of mycosis fungoides that is more common in young populations. Although phototherapy is the most used treatment for pediatric patients with hMF, there are currently no ...
Sarah Muir, Shangyi Fu, Sarah Kesaria, Juan Pinto-Cuberos, Ayezel Munoz-Gonzalez, Alba Guglielmo   +5 more
wiley   +1 more source

Praxisempfehlungen für die Therapie und Überwachung von Mogamulizumab‐Patienten in Deutschland

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 3, Page 341-356, March 2025.
Zusammenfassung Mycosis fungoides (MF) und Sézary‐Syndrom (SS) sind die häufigsten Subtypen der heterogenen Gruppe der kutanen T‐Zell‐Lymphome (CTCL). Mit der Erweiterung der Therapielandschaft sind in den letzten Jahren neue Behandlungsoptionen verfügbar geworden, allen voran der gegen den C‐C‐Chemokinrezeptor 4 (CCR4) gerichtete monoklonale ...
Chalid Assaf, Nina Booken, Edgar Dippel, Gabor Dobos, Hans‐Theodor Eich, Claus‐Detlev Klemke, Christina Mitteldorf, Jan P. Nicolay, Sebastian Theurich, Marion Wobser, Rudolf Stadler   +10 more
wiley   +1 more source

Posttransplantation course after allogeneic stem cell transplantation in a patient with advanced mycosis fungoides—Balancing relapse and rejection

JEADV Clinical Practice, Volume 3, Issue 5, Page 1660-1664, December 2024.
Capsule Summary To date, the only potentially curative treatment option for advanced mycosis fungoides (MF) is allogeneic hematopoietic stem‐cell‐transplantation (alloHSCT). We report on a patient with MF who received allo‐HSCT due to rapid progression of the disease.
Inga Hansen‐Abeck, Chiara L. Blomen, Finn Abeck, Leopold Torster, Stefan W. Schneider, Nina Booken   +5 more
wiley   +1 more source

Pegylated interferon‐α2a in cutaneous T‐cell lymphoma – a multicenter retrospective data analysis with 70 patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 22, Issue 11, Page 1489-1497, November 2024.
Summary Background Interferon‐alpha is an important therapeutic option for the treatment of the cutaneous T‐cell lymphomas (CTCL). Since the approved recombinant interferon‐α‐2a (IFN‐α2a) has no longer been produced since January 2020, pegylated interferon‐α2a (pegIFN‐α2a) can be used as an alternative treatment, even though it is not approved for the ...
Inga Hansen‐Abeck, Glenn Geidel, Finn Abeck, Julian Kött, Rohat Cankaya, Gabor Dobos, Christina Mitteldorf, Jan P. Nicolay, Jana D. Albrecht, Christian Menzer, Elisabeth Livingstone, Miriam Mengoni, Andreas D. Braun, Marion Wobser, Claus‐Detlev Klemke, Sabine Tratzmiller, Chalid Assaf, Patrick Terheyden, Kai‐Christian Klespe, Stefan W. Schneider, Nina Booken   +20 more
wiley   +1 more source